Monographs: Dosage forms: Specific monographs: Clindamycin hydrochloride capsules (Clindamycini hydrochloridi capsulae)

Category. Antibacterial.

Storage. Clindamycin hydrochloride capsules should be kept in a tightly closed container.

Additional information. Strength in the current WHO Model List of Essential Medicines (EML): 150 mg (as hydrochloride). Strengths in the current EML for Children: 150 mg (as hydrochloride).

Labelling. The designation on the container should state the quantity of clindamycin hydrochloride in terms of the equivalent amount of clindamycin. 150 mg of clindamycin is approximately equivalent to 162.9 mg of clindamycin hydrochloride.

Requirements

Comply with the monograph for Capsules.

Definition. Clindamycin hydrochloride capsules contain clindamycin hydrochloride. They contain not less than 90.0% and not more than 110.0% of the amount of C 18H33ClN2O5S stated on the label.

Identity tests

Either tests A and D or B and D or C and D may be applied

A. Shake a quantity of the contents of the capsules containing the equivalent of 30 mg of clindamycin with 15 mL of dichloromethane R, filter and evaporate the filtrate to dryness. Carry out the examination as described under 1.7 Spectrophotometry in the infrared region The infrared absorption spectrum is concordant with the spectrum obtained from clindamycin hydrochloride RS, treated in the same way as the test substance, or with the reference spectrum of clindamycin hydrochloride.

B. Carry out the test as described under 1.14.1 Chromatography, Thin-layer chromatography using silica gel R1 as the coating substance and the upper layer of a mixture of 19 volumes of 2-propanol R, 38 volumes of a solution of ammonium acetate (~150 g/L) TS adjusted to pH 9.6 with ammonia (~260 g/L) TS and 43 volumes of ethyl acetate R as the mobile phase. Apply separately to the plate 5 μL of each of the following three solutions. For solution (A) shake a quantity of the contents of the capsules equivalent to 10 mg of clindamycin with 10 mL of methanol R, filter and use the clear filtrate. For solution (B) use 1 mg of clindamycin hydrochloride RS per mL of methanol R. For solution (C) use 1 mg of clindamycin hydrochloride RS and 1 mg of lincomycin hydrochloride R per mL of methanol R. After removing the plate from the chromatographic chamber allow it to dry in air and spray with potassium permanganate (~1 g/L) TS. Examine the chromatogram in daylight.

The principal spot obtained with solution (A) corresponds in position, appearance and intensity with that obtained with solution (B). The test is not valid unless the chromatogram obtained with solution (C) shows two clearly separated spots.

C. Carry out the test as described under 1.14.1 Chromatography, High-performance liquid chromatography using the conditions given under “Assay”. The retention time of the principal peak in the chromatogram obtained with solution (1) corresponds to the retention time of the peak due to Clindamycin in the chromatogram obtained with solution (2).

D. Shake a quantity of the contents of the capsules containing 50 mg of clindamycin with 5 mL of water and filter. The clear filtrate yields the reactions described under 2.1 General identification tests as characteristic of chlorides.

Water. Determine as described under 2.8 Determination of water by the Karl Fischer method, method A, using a quantity of the contents of the capsules equivalent to 0.5 g of Clindamycin; the water content is not more than 70 mg/g.

Dissolution. Carry out the test as described under 5.5 Dissolution test for solid oral dosage forms using as the dissolution medium 500 mL of dissolution buffer, pH 6.8, TS and rotating the paddle at 75 revolutions per minute. At 30 minutes withdraw a sample of 10 mL of the medium through an in-line filter and use the filtrate as solution (1). For solution (2) dissolve a suitable amount of clindamycin hydrochloride RS in dissolution medium to obtain a concentration of 326 µg per mL.

Carry out the test as described under 1.14.1 Chromatography, High-performance liquid chromatography using the chromatographic conditions as described under “Assay”.

For each of the capsules tested calculate the amount of clindamycin (C18H33ClN2O5S) in the medium, using the declared content of C18H33ClN2O5S,HCl in clindamycin hydrochloride RS. Evaluate the results as described under 5.5 Dissolution test for solid oral dosage forms, Acceptance criteria. The amount clindamycin in solution for each capsule is not less than 75% (Q) of the amount declared on the label.

Related substances. Carry out the test as described under 1.14.1 Chromatography, High-performance liquid chromatography using the conditions given below under “Assay”.

Prepare the following solutions in the mobile phase. For solution (1) transfer a weighed quantity of the contents of the capsules, containing the equivalent of about 100 mg of clindamycin into a 25 mL volumetric flask. Add about 20 mL of mobile phase and sonicate for 10 minutes. Dilute to volume with mobile phase, mix and filter. For solution (2) dilute 2.0 mL of solution (1) to 100.0 mL.

Inject alternately 20 μL each of solutions (1) and (2). Record the chromatograms for 2 times the retention time of clindamycin (retention time about 10 minutes).

In the chromatogram obtained with solution (1) the following impurities, if present, are eluted at the following relative retention with reference to clindamycin: impurity A (lincomycin) about 0.4; impurity B (clindamycin B) about 0.65; impurity C (7-epiclindamycin) about 0.8.

In the chromatogram obtained with solution (1):

  • the area of any peak corresponding to either impurity B or impurity C is not greater than the area of the principal peak in the chromatogram obtained with solution (2) (2.0%);
  • the area of any peak, corresponding to impurity A is not greater than 0.5 times the area of the principal peak in the chromatogram obtained with solution (2) (1.0%).

Assay. Carry out the test as described under 1.14.1 Chromatography, High-performance liquid chromatography using a stainless steel column (25 cm × 4.6 mm) packed with particles of silica gel, the surface of which has been modified with chemically-bonded octadecylsilyl groups (5 μm). As the mobile phase use a mixture of 45 volumes of acetonitrile R and 55 volumes of a 6.8 g/L solution of potassium dihydrogen phosphate R adjusted to pH 7.5 with potassium hydroxide (~400 g/L) TS.

Prepare the following solutions in mobile phase. For solution (1) weigh and mix the contents of 20 capsules. Transfer a quantity of the mixed contents equivalent to about 100 mg of Clindamycin, accurately weighed, into a 100 mL volumetric flask. Add about 80 mL of the mobile phase, sonicate for 10 minutes, make up to volume with the mobile phase, mix and filter. For solution (2) use a solution containing 1.1 mg of Clindamycin hydrochloride RS per mL.

Operate with a flow rate of 1.0 mL per minute. As a detector use an ultraviolet spectrophotometer set at a wavelength of 210 nm.

Inject alternately 20 μL each of solutions (1) and (2).

Measure the areas of the peaks corresponding to clindamycin obtained in the chromatograms of solution (1) and (2) and calculate the percentage content of clindamycin (C18H33ClN2O5S) in the capsules, using the declared content of C18H33ClN 2O5S,HCl in clindamycin hydrochloride RS. Each mg of C18H33ClN2O5S,HCl (clindamycin hydrochloride) is equivalent to 0.9209 mg of C18H 33ClN2O5S (clindamycin).

Impurities. The impurities limited by the requirements of this monograph are impurity A, B and C listed in the monograph for Clindamycin hydrochloride.

to previous sectionto next section